索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]万艺 王群山.导管消融联合左心耳封堵一站式治疗非瓣膜性心房颤动[J].国际心血管病杂志,2019,04:193-197.
点击复制

导管消融联合左心耳封堵一站式治疗非瓣膜性心房颤动(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2019年04期
页码:
193-197
栏目:
综述
出版日期:
2019-09-27

文章信息/Info

Title:
-
作者:
万艺 王群山
200025 上海交通大学医学院附属新华医院心内科
Author(s):
-
关键词:
非瓣膜性心房颤动;  抗凝药物;  左心耳封堵术;  导管消融
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2019.04.001
文献标识码:
-
摘要:
导管消融联合左心耳封堵一站式治疗非瓣膜性房颤(NVAF)具有较多优点,受到广泛关注。该文介绍一站式治疗NVAF的发展历程,一站式治疗NVAF的联合顺序、适应证、导管消融类型及左心耳封堵的研究进展。
Abstract:
-

参考文献/References

[ 1 ] Price MJ. Left atrial appendage occlusion with the WATCHMANTM for stroke prevention in atrial fibrillation[J]. Rev Cardiovasc Med, 2014, 15(2):142-151.
[ 2 ] Lee S, Choi D, Jeong WK, et al. Frequency of hemorrhagic complications on abdominal CT in patients with warfarin therapy[J]. Clin Imaging, 2016, 40(3):435-439.
[ 3 ] Aleksandrov AP, Mirkov I, Zolotarevski L, et al. Oral warfarin intake affects skin inflammatory cytokine responses in rats[J]. Environ Toxicol Pharmacol, 2017, 54:93-98.
[ 4 ] Agaba P, Kildow BJ, Dhotar H, et al. Comparison of postoperative complications after total hip arthroplasty among patients receiving aspirin, enoxaparin,warfarin, and factor Xa inhibitors[J]. J Orthop, 2017, 14(4):537-543.
[ 5 ] Cappato R, Calkins H, Chen SA, et al. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation[J]. Circ Arrhythm Electrophysiol, 2010, 3(1):32-38.
[ 6 ] January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the heart rhythm society[J]. Circulation, 2014, 64(21):2305-2307.
[ 7 ] Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS[J]. Eur Heart J, 2016, 37(38):2893-2962.
[ 8 ] Holmes DR, Kar S, Price MJ, et al. Prospective randomized evaluation of the watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial[J]. J Am Coll Cardiol, 2014, 64(1):1-12.
[ 9 ] Reddy VY, Doshi SK, Kar S, et al. 5-year outcomes after left atrial appendage closure from the PREVAIL and PROTECT AF trials[J]. J Am Coll Cardiol, 2017, 70(24):2964-2975.
[10] Swaans MJ, Post MC, Rensing BJ. Ablation for atrial fibrillation in combination with left atrial appendage closure: first results of a feasibility study[J]. J Am Heart Assoc, 2012, 1(5):e002212.
[11] Swaans MJ, Alipour A, Rensing BJ, et al. Catheter ablation in combination with left atrial appendage closure for atrial fibrillation[J]. J Vis Exp, 2013, 72:e3818.
[12] Lakkireddy D, Sridhar MA, Kanmanthareddy A, et al. Left atrial appendage ligation and ablation for persistent atrial fibrillation: the LAALA-AF registry[J]. JACC Clin Electrophysiol, 2015, 1(3):153-160.
[13] Calvo N, Salterain N, Arguedas H, et al. Combined catheter ablation and left atrial appendage closure as a hybrid procedure for the treatment of atrial fibrillation[J]. Europace, 2015, 17(10):1533-1540.
[14] Alipour A, Swaans MJ, Van Dijk VF, et al. Ablation for atrial fibrillation combined with left atrial appendage closure[J]. JACC Clin Electrophysio, 2015, 1(6):486-495.
[15] Phillips KP, Walker DT, Humphries JA. Combined catheter ablation for atrial fibrillation and watchman left atrial appendage occlusion procedures: five-year experience[J]. J Arrhythm, 2016, 32(2):119-126.
[16] Fassini G, Conti S, Moltrasio M, et al. Concomitant cryoballoon ablation and percutaneous closure of left atrial appendage in patients with atrial fibrillation[J]. Europace, 2016, 18(11):1705-1710.
[17] Wintgens L, Romanov A, Phillips KA, et al. Combined atrial fibrillation ablation and left atrial appendage closure: long-term follow-up from a large multicentre registry[J]. Europace, 2018, 20(11):1783-1789.
[18] Du XF, Chu HM, He B, et al. Optimal combination strategy of left atrial appendage closure plus catheter ablation in a single procedure in patients with nonvalvular atrial fibrillation[J]. J Cardiovasc Electrophysiol, 2018, 29(8):1089-1095.
[19] Heeger CH, Rillig A, Lin T, et al. Feasibility and clinical efficacy of left atrial ablation for the treatment of atrial tachyarrhythmias in patients with left atrial appendage closure devices[J]. Heart Rhythm, 2015, 12(7):1524-1531.
[20] Reissmann B, Metzner A, Kuck KH. Cryoballoon ablation versus radiofrequency ablation for atrial fibrillation[J]. Trends Cardiovasc Med, 2017, 27(4):271-277.
[21] Boersma LV, Wijffets MC, Oral H, et al. Pulmonary vein isolation by duty-cycled bipolar and unipolar radiofrequency energy with a multielectrode ablation catheter[J]. Heart Rhythm, 2008, 5(12):1635-1642.
[22] Mulder AA, Wijffels MC, Wever EF, et al. Pulmonary vein isolation and left atrial complex-fractionated atrial electrograms ablation for persistent atrial fibrillation with phased radio frequency energy and multi-electrode catheters: efficacy and safety during 12 months follow-up[J]. Europace, 2011, 13(12):1695-1702.
[23] Beukema RP, Beukema WP, Smit JJ, et al. Efficacy of multi-electrode duty-cycled radiofrequency ablation for pulmonary vein disconnection in patients with paroxysmal and persistent atrial fibrillation[J]. Europace, 2010, 12(4):502-507.
[24] Davies EJ, Clayton B, Lines I, et al. Persistent atrial fibrillation ablation using the tip-versatile ablation catheter[J]. Heart Lung Circ, 2016, 25(7):645-651.
[25] Weerasooriya R, Khairy P, Litalien J, et al. Catheter ablation for atrial fibrillation: are results maintained at 5 years of follow-up?[J]. J Am Coll Cardiol, 2011, 57(2):160-166.
[26] Nakai T, Lesh MD, Gerstenfeld EP, et al. Percutaneous left atrial appendage occlusion(PLAATO)for preventing cardioembolism: first experience in canine model[J]. Circulation, 2002, 105(18):2217-2222.
[27] Boersma LV, Ince H, Kische S, et al. Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-year follow-up outcome data of the EWOLUTION trial[J]. Heart Rhythm, 2017, 14(9):1302-1308.
[28] Tzikas A, Meier B, Sievert H, et al. Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicenter experience with the AMPLATZER cardiac plug[J]. EuroIntervention, 2016, 11(10):1170-1179.
[29] Saw J, Tzikas A, Shakir S, et al. Incidence and clinical impact of device-associated thrombus and peri-device leak following left atrial appendage closure with the amplatzer cardiac plug[J]. JACC Cardiovasc Interv, 2017, 10(4):391-399.
[30] Carlson SK, Doshi RN. Termination of anticoagulation therapy at 45 days after concomitant atrial fibrillation catheter ablation and left atrial appendage occlusion resulting in device-related thrombosis and stroke[J]. Heart Rhythm Case Rep, 2017, 3(1):18-21.

备注/Memo

备注/Memo:
基金项目:国家自然科学基金(81873485)
作者单位:200025 上海交通大学医学院附属新华医院心内科
通信作者:王群山,Email:mrqunshanwang@163.com.
更新日期/Last Update: 2019-09-27